MIGS – eine Off-label-Option für eine therapierefraktäre, steroidinduzierte okuläre Hypertension

Hohberger, Bettina; Haug, Marius; Bergua, Antonio; Laemmer, Robert

doi:10.1007/s00347-019-0898-y

Cited by 3 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Xen45 gel stent is known to significantly reduce IOP, even in difficult cases as well as in patients with refractory glaucoma 20 , 21 , 22 . Widder et al showed promising success rates after Xen45 gel stent implantation, lowering IOP from 24.3 ± 6.6 mmHg to 16.8 ± 7.6 mmHg after a mean follow-up time of 8.5 months.…”

Section: Discussionmentioning

confidence: 99%

Influence of Mitomycin C on the Therapeutic Success of Stand-Alone Xen45 Gel Stents and Its Combination with Cataract Surgery in Open-Angle Glaucoma Patients

Denkel

Hohberger

Laemmer

2021

Klin Monbl Augenheilkd

Self Cite

View full text Add to dashboard Cite

Purpose Minimally invasive glaucoma surgery (MIGS), like Xen45 gel stents, is known as effective therapy in lowering intraocular pressure (IOP); however, fibrotic reactions are a common problem in postoperative management. It was the aim of this study to investigate the therapeutic success of Xen45 gel stents as a stand-alone technique (Xen) and combined with cataract surgery (XenPhaco), and with antimetabolites (mitomycin C, MMC) in open-angle glaucoma patients. Methods Retrospective analysis was performed of 199 eyes of 177 glaucoma patients of the Department of Ophthalmology, University of Erlangen Nürnberg, and from the Erlangen Glaucoma Registry (NCT00494923; ISSN 2191-5008, CS-2011) who underwent implantation of a Xen45 gel stent. Therapeutic success was defined as IOP reduction of ≥ 20% on the same or less anti-glaucomatous medication after 12 months compared to preoperative and without any additional glaucoma-related surgery (except bleb needling). IOP reduction, reduction in local anti-glaucomatous eye drops, and intra- and postoperative complications were monitored. Results Stand-alone Xen45 gel stent: therapeutic success was reached in 39% (–MMC) and 55% (+MMC). Failure rate was 61% (–MMC) and 45% (+MMC). XenPhaco: therapeutic success was achieved in 57% (–MMC) and 46% (+MMC). Failure rate was 43% (-MMC) and 54% (+MMC). Data were not different for group and subgroup analyses (p > 0.05). Conclusions The use of MMC seemed to increase the therapeutic success rate after stand-alone Xen45 gel stent implantation and combined with cataract surgery, yet statistical significant was not reached.

show abstract

Section: Discussionmentioning

confidence: 99%